Asset profile
PLB1001
Small molecule
Evidence outlook · registrational
Non-Small Cell Lung Cancer: registrational readout pending
Entered Phase 3 on weak signal mid-stage evidence. Registrational readout expected around 2026-09-30.
NCT04258033: The study was an open-label, single-arm trial of 145 participants with no placebo or active comparator, so treatment effects cannot be separated from the disease’s natural course or other factors. Its primary endpoint was RECIST 1.1 objective response rate, but results were not posted, so whether the endpoint was met is unknown.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
September 2026 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.